Top executives at Neumora Therapeutics (NMRA) recently engaged in coordinated stock sales, with CEO Paul Berns, COO Aurora Daljit Singh, and President Joshua Pinto cashing out shares totaling over $77,000. These transactions follow positive analyst attention due to favorable Phase Ib data for NMRA-511, a drug for Alzheimer’s disease agitation, which sparked a more optimistic valuation outlook for the company. Despite the insider selling, TipRanks’ AI Analyst, Spark, rates NMRA as “Neutral” due to weak financial performance tempered by constructive technical positioning and a promising pipeline.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Top Neumora Executives Quietly Cash Out in Coordinated Stock Sell-Off
Top executives at Neumora Therapeutics (NMRA) recently engaged in coordinated stock sales, with CEO Paul Berns, COO Aurora Daljit Singh, and President Joshua Pinto cashing out shares totaling over $77,000. These transactions follow positive analyst attention due to favorable Phase Ib data for NMRA-511, a drug for Alzheimer’s disease agitation, which sparked a more optimistic valuation outlook for the company. Despite the insider selling, TipRanks’ AI Analyst, Spark, rates NMRA as “Neutral” due to weak financial performance tempered by constructive technical positioning and a promising pipeline.